NEWS AND EVENTS
KEEP IN TOUCH WITH US
04 Apr
2019

How Hong Kong Biotechnology enter the world stage

(Chinese printed version only)

<Sing Tao Daily>

11 Mar
2019

Global Influenza drives medical needs, Aptorum Group seizes opportunities to create value

<中国财经观察网>
(Chinese version only)

  2018年年初,一篇名为《流感下的北京中年》的文章登上微博热搜、刷屏微信朋友圈。人们在感慨生命脆弱的同时,也开始更加重视流感等传染疾病的防治。在健康需求上升和科学技术发展的双重趋势下,运用先进科技探索未知领域,依靠技术发展满足人类需求,已成为知临集团(NASDAQ: APM)等众多医药科研机构的共同目标。

  全球性流感引发广泛关注 知临首创抗流感药物展现价值

  国家卫健委近日发布的《2019年1月全国法定传染病疫情概况》显示,2019年1月份我国流行性感冒发病数为60.85万例,死亡143人,已超过2017年全年报告流感死亡人数的三倍,约与2018年全年报告死亡人数相当。此外,根据印度国家疾病控制中心公布的数据,印度2019年以来已确诊超过1.2万例甲型H1N1流感病例,其中377人死亡。而法国公共卫生部门2月20日发布的流感疫情监测报告也显示,2018年10月1日至2019年2月3日,法国流感疫情已造成约2800人死亡。全球性的流感疫情已经引发人们越来越多的关注。

  研究结果表明,每年流感爆发导致约3至5百万宗严重的流感病毒感染病例,引致29至65万宗死亡个案,其中50%到80%的病例是都是由甲型流感引起的。针对全球范围内高传染性、高发病率、并发症严重的流行性感冒,香港知临集团通过深入的研究和探索,首创了针对核蛋白的新型抗流感候选小分子ALS-1。这种新型抗流感小分子药物能抑制常见的H1N1病毒、H3N2亚型和H5N1病毒,可以有效治疗甲型流感病毒引起的病毒性感染。此外,ALS-1作用于核蛋白这一独特的靶点,也使其与所有目前市场上存在耐药性问题的抗甲型流感病毒药物区别开来。这份成果不仅代表着医疗史上一项重要发现,对流行性感冒的防治具有特殊意义,更展现出广阔的市场空间和良好的发展前景。据预测,2025年全球流感药物市场规模预期将达到12亿美元,知临集团的研究成果如在未来得到推广应用,不仅能填补人类传染病医疗技术上的空白,也将同时创造极高的商业价值。

  探索传染病非抗生素疗法 开创免疫治疗新纪元

  除了针对甲型流感的药物研究外,知临集团一直关注各类传染病及常见病的预防和治疗,其重要科研项目还包括抗“超级细菌”的药物研究等。“超级细菌”的原名为耐甲氧西林金黄色葡萄球菌(MRSA),是由于抗生素的滥用使金黄葡萄球菌不断变异、演化出抗药性所产生恶性细菌。金黄葡萄球菌广泛分布在空气、土壤、水源中,是一类十分常见的病菌。据研究结果统计,全球约有5,300万人为金黄色MRSA带菌者。在美国,每年约有126,000人因此类细菌的感染住院,其中约有94,000人发生严重感染,并且导致大约19,000人死亡。

  在探索能抵御“超级细菌”的药物的过程中,由于MRSA已经对大部分现有的抗生素药物产生了耐药性,知临集团便与香港大学合作共同研发了对抗“超级细菌”的新型非抗生素合成抑制剂ALS-4。这是化学遗传学第一次被尝试用来解决MRSA感染问题。这一革命性的理念和化学遗传学应用的发现,构成了发现ALS-4的基础,在瑞士日内瓦第四届国际预防和感染控制会议(ICPIC 2017)上荣获学术创新一等奖,获得科学界的高度认可。ALS-4小分子药物可抑制用来保护金黄色葡萄球菌的金黄色素的产生而不杀死细菌,进一步使得免疫系统能够清除MRSA。未来,随着后抗生素时代的发展变化,如果这项研究成果成功落地并商品化,将标志着全人类依赖抗生素的旧时代会彻底改变。

  成功登陆纳斯达克资本市场 募集资金用于未来医疗研究

  医学革命更迭总是源于人类的新需求,在健康需求不断提高、技术发展日趋快速的背景下,知临集团始终致力于探索医学的空白领域。事实上,知临集团涉猎医药与非医药两个板块,除了抗甲型流感、抗MRSA的药物研究外,也潜心研发适用于不同领域的候选药品及候选医疗器械。截至2017年底,知临集团已经在脑神经、传染病、胃肠病、肿瘤和自然健康等领域取得11项专利技术的独家授权,在手术机器人(19.54 +0.10%,诊股)、优越医疗服务等非医药领域也享有丰厚的研究成果。

  为了未来更深入的研究以及成果的推广应用,知临集团在深耕学术领域的同时也积极探索着资本市场发展途径。2018年9月,知临集团披露招股书并申请于美股纳斯达克市场上市。经过多地路演及深入的机构交流,知临集团得到平安保险及安德思资产管理(香港)有限公司合资成立的私募基金安德思平安机会基金及一众投资者支持,并于美国东部时间12月18日在纳斯达克全球市场正式开始交易。

  知临集团本次公开发售以每股15.80美元的价格发行了761,419股A类普通股,在不扣除承销商折扣、佣金以及其他发行费用的情况下,此次发售共筹集到12,030,420美元。据了解,本次募集资金将用于开发针对流感治疗的ALS-1项目、针对MRSA的ALS-4项目以及治疗子宫内膜异位症的NLS-1项目。预计未来,知临集团将通过更加深入的研究和探索,开发各类创新医学治疗应用,在满足人类医疗需求的同时不断创造商业投资价值。

(Source: http://www.xsgou.com/biz/finance/146461.html)

17 Dec
2018

Aptorum Group Limited Announces Closing of Initial Public Offering

<BUSINESS WIRE>

Aptorum Group Limited (“Aptorum”, or the “Company”), a pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs, today announced the closing of its initial public offering (“IPO” or the “Offering”) of 761,419 Class A Ordinary Shares, at a public offering price of $15.80 per share. The aggregate gross proceeds to Aptorum from the offering were $12,030,420, before deducting underwriting discounts and commissions and other offering expenses. While certain selling shareholders are offering to resell up to 1,595,235 Class A Ordinary Shares subject to certain lock-up periods, as applicable, none of the gross proceeds of the IPO will be used to purchase the selling shareholders’ securities nor will the Company receive any proceeds from the selling shareholders’ resale. The shares are expected to commence trading on The NASDAQ Global Market on December 18, 2018 at any time between 11:00 a.m. to 12:00 p.m. ET, under the ticker symbol “APM.”

Boustead Securities, LLC, China Renaissance Securities (HK) Limited, and AMTD Global Markets Limited acted as co-underwriters for the offering.

A registration statement has been filed with the SEC and became effective on December 3, 2018. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Boustead Securities, LLC, email: offerings@boustead1828.com or by calling +1 (949) 502-4409 or standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 265, Irvine, CA 92618, USA.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aptorum Group Limited

We are a pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing a broad range of therapeutic and diagnostic technologies to tackle unmet medical needs. We have obtained exclusive licenses for our technologies. In addition, we are also developing certain proprietary technologies as product candidates. We are pursuing therapeutic and diagnostic projects (including projects seeking to use extracts or derivatives from natural substances to treat diseases) in neurology, infectious diseases, gastroenterology, oncology and other disease areas. We also have projects focused on surgical robotics. In addition, we opened a medical clinic, AML Clinic, in June 2018. Its initial focus is on treatment of chronic diseases resulting from modern sedentary lifestyles and aging population. For more information about the Company, please visit www.aptorumgroup.com.

About Boustead Securities, LLC

Boustead Securities, LLC ("Boustead") is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead's core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States and around the world, Boustead's team moves quickly and provides a broad spectrum of sophisticated financial advice and services. For more information, visit www.boustead1828.com.

About China Renaissance Securities (Hong Kong) Limited

China Renaissance (“CR”) is a leading financial institution that combines private placement advisory, M&A advisory, securities underwriting, research, sales and trading, investment management and other financial services. Providing one-stop financial services across mainland China, Hong Kong and the United States, CR operates a competitive and unique international network that connects China’s capital markets with the rest of the world, serving new economy entrepreneurs and investors globally. CR has offices in Beijing, Shanghai, Hong Kong and New York, with approximately 600 employees. As of March 31, 2018, CR had advised on approximately 700 transactions worth over US$100 billion since the inception, and CR had AUM of approximately US$4.1 billion in new economy investments. For more information, visit www.huaxing.com.

About AMTD Global Markets Limited

AMTD Global Markets Limited (“AMTD”) is a Hong Kong-based comprehensive financial institution dedicated to serving and bridging capital and resources across mainland China, Hong Kong and the globe. As one of the largest Hong Kong-based non-bank financial institution, AMTD has been widely recognized as a pre-eminent capital markets player with leading cross-border investment banking capabilities in Asia. Founded in 2003, AMTD has a long history of promoting technological innovations and the development of New Economy sectors, especially in the fields of FinTech, Artificial Intelligence and Healthcare. For more information, visit www.amtdgroup.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Specifically, the Company's statements regarding listing on the NASDAQ Global Market and the completion of the IPO are forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, risks and uncertainties related to the satisfaction of the customary closing conditions related to the IPO and the listing on NASDAQ. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward‐looking statements to reflect events or circumstances that arise after the date hereof unless required by the applicable laws, regulations or rules.

Contacts
At the Company:
Sabrina Khan, CFO
Aptorum Group Limited
Phone: +852 2117 6611
Email: investor.relations@aptorumgroup.com

(Source: https://www.businesswire.com/news/home/20181217005879/en/Aptorum-Group-Limited-Announces-Closing-Initial-Public)

×
×
×
×
Terms of Use

This Website contains information concerning Aptorum Group Limited (“Aptorum Group”) and its affiliates that may be useful to Aptorum Group’s customers, suppliers, employees, directors and shareholders, as well as members of the general public. However, by using this Website you are accepting all of the terms of this disclaimer notice, including exclusions and limitations of liability. If you do not agree with anything in this notice, you should not use this Website.

Aptorum Group does not claim ownership of the materials and product images on the Website that are provided to us by our third party suppliers.

Where our Website contains links to other sites and resources provided by third parties, these links are provided for your information only. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them. These links are provided solely as a convenience to you and not as an endorsement by us of the contents on such third party websites.

While reasonable efforts are made to ensure that the contents of this Website are accurate, this Website and its contents are provided on an “as is,” “as available” basis, without warranties of any kind, including any warranty that the Website will be kept up to date, be true and not misleading, or that the Website will always (or ever) be available for use. Aptorum Group and its affiliates disclaim all warranties, express or implied, with respect to the Website and its contents, including, without limitation, any warranties of accuracy, completeness, timeliness, non-infringement, title, merchantability, or fitness for a particular purpose. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.

In no event will Aptorum Group or its affiliates be liable for any incidental, indirect, consequential, or special damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of profits, contracts, goodwill, data, information, income, anticipated savings, or business relationships, whether or not Aptorum Group or its affiliates have been advised of the possibility of such damage, arising out of or in connection with the use of this Website or its contents or any other sites linked to this Website.

If you have any concerns about material which appears on our Website, please contact us. We have the right and the ability to remove immediately from our Website any material that is infringing, defamatory, offensive, abusive, harming, deceptive, threatening or otherwise illegal.